ストックスクリーナーアプリを入手
12.18
0.25%
-0.03
前日終値:
$12.21
開ける：
$12.21
24時間の取引高:
1.14M
Relative Volume:
0.89
時価総額：
$615.37M
収益：
-
当期純損益:
$-156.39M
株価収益率:
-3.3008
EPS:
-3.69
ネットキャッシュフロー:
$-123.06M
1週間 パフォーマンス:
-6.45%
1か月 パフォーマンス:
-9.51%
6か月 パフォーマンス:
+5.55%
1年 パフォーマンス:
+5.18%
1日の値動き範囲:
$11.93
$12.36
1週間の範囲:
$11.54
$13.28
52週間の値動き範囲:
$7.30
$17.28
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
名前
Kalvista Pharmaceuticals Inc
セクター
電話
(857) 999-0075
住所
200 CROSSING BOULEVARD, FRAMINGHAM, MA
KALV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
12.18 | 616.89M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-31 | 開始されました | JMP Securities | Mkt Outperform |
| 2025-01-07 | 開始されました | TD Cowen | Buy |
| 2024-12-18 | 開始されました | BofA Securities | Buy |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-29 | 開始されました | SVB Leerink | Outperform |
| 2019-03-20 | 開始されました | Needham | Buy |
| 2018-10-30 | 開始されました | Jefferies | Buy |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 開始されました | BTIG Research | Buy |
すべてを表示
Kalvista Pharmaceuticals Inc (KALV) 最新ニュース
Is KalVista Pharmaceuticals Inc. forming a bottoming base2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
What drives KalVista Pharmaceuticals Inc 4XC1 stock priceEarnings Per Share Trends & Affordable Trading Strategies - earlytimes.in
Can KalVista Pharmaceuticals Inc. stock sustain free cash flow growthJuly 2025 Highlights & Weekly Breakout Opportunity Watchlist - newser.com
Is KalVista Pharmaceuticals Inc. (4XC1) stock included in top ETFsMarket Risk Analysis & Long-Term Safe Investment Ideas - newser.com
KalVista Pharmaceuticals Completes Convertible Notes Sale - TipRanks
Custom strategy builders for tracking KalVista Pharmaceuticals Inc.2025 Dividend Review & Breakout Confirmation Trade Signals - newser.com
Published on: 2025-09-28 22:29:02 - earlytimes.in
With HAE Drug EKTERLY Off To A Strong Start, Is Now The Time To Keep An Eye On KalVista Stock? - Nasdaq
KalVista prices upsized offering of $125M of 3.250% notes due 2031 - MSN
KalVista to offer $110M in convertible notes; shares down 10% - MSN
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress - Business Wire
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 6.9%What's Next? - MarketBeat
Ekterly approved as on-demand therapy for HAE in EU, Switzerland - Angioedema News
KalVista Prices Upsized Offering of $125.0 Million of 3.250 Convertible Senior Notes Due 2031 - MarketScreener
KalVista Pharma falls after $125 mln convertible debt sale - TradingView
KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031 - Business Wire
KalVista Pharmaceuticals Prices $125 Million Notes Offering - MarketScreener
KalVista plans to offer $110 million in convertible notes By Investing.com - Investing.com Canada
KalVista prices $125 million convertible senior notes offering - Investing.com
KalVista prices $125 million convertible senior notes offering By Investing.com - Investing.com Nigeria
Kalvista Pharmaceuticals stock falls after convertible notes offering By Investing.com - Investing.com Canada
Kalvista Pharmaceuticals announces proposed offering of $110.0 million of convertible senior notes - MarketScreener
KalVista plans to offer $110 million in convertible notes - Investing.com
Kalvista Pharmaceuticals stock falls after convertible notes offering - Investing.com India
KalVista (KALV) Plans $110M Convertible Senior Notes Offering - GuruFocus
KalVista Pharmaceuticals Proposes Private Offering of $110 Million of Convertible Notes; Shares Fall After Hours - MarketScreener
KalVista Pharma falls after announcing $110 mln convertible debt offering - TradingView
KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes - The Joplin Globe
KalVista Pharmaceuticals Experiences Evaluation Revision Amidst Mixed Market Signals - Markets Mojo
Hereditary Angioedema Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
KalVista Pharmaceuticals, Inc. $KALV Shares Purchased by Rhumbline Advisers - Defense World
Hereditary Angioedema Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com
KalVista’s Regulatory Victory Meets Market Skepticism - AD HOC NEWS
KalVista’s Ekterly approved in EU and Switzerland - The Pharma Letter
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema - BioSpace
Decliners Report: What analysts say about KalVista Pharmaceuticals Inc stockJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - خودرو بانک
KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs - MSN
Analyzing KalVista Pharmaceuticals Inc. with risk reward ratio charts2025 Investor Takeaways & Daily Price Action Insights - newser.com
Hereditary Angioedema Pipeline Drugs Report 2025 - openPR.com
KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year - Stocktwits
KalVista’s oral HAE treatment Ekterly receives EU and Swiss approval - Investing.com India
Earnings Miss: Can KalVista Pharmaceuticals Inc. deliver consistent dividendsJuly 2025 Market Mood & Low Risk Profit Maximizing Plans - khodrobank.com
KalVista (KALV) Secures EU Approval for Hereditary Angioedema Tr - GuruFocus
KalVista’s oral HAE treatment Ekterly receives EU and Swiss approval By Investing.com - Investing.com Nigeria
Gold miners, Perpetua Resources, KalVista Pharmaceuticals - TradingView
KalVista (KALV) Gains European and Swiss Approval for Ekterly - GuruFocus
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY - Business Wire
Kalvista Pharmaceuticals Inc (KALV) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):